Mineralys Therapeutics announced on March 18, 2025, the closing of its recently completed public offering, which included the full exercise of the underwriters’ option to purchase additional shares. An additional 1,944,444 shares of common stock were sold at $13.50 per share.
After giving effect to the sale of these additional shares, the aggregate gross proceeds to Mineralys from the offering totaled approximately $201.2 million. All of the securities sold in the offering were sold by Mineralys.
The net proceeds from this offering are intended to fund the clinical development of lorundrostat, including research and development and manufacturing, and pre-commercialization activities. This capital infusion also supports working capital and general corporate purposes, strengthening the company's financial runway.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.